EvaluatePharma: Orphan Drug Report 2017
Mmmmm ....very interesting report. I am sure SPECO1 and JFM1330 will be better than me to comment this report but I will try to bring an humble contribution here :o) . By the way I take this opportunity to thank them (and many others on this board (Palinc, Smartmitchel,....)) for their so usefull contribution.
So to establish the price of Trogarzo, we know that TH and Taimed took several criterias in consideration and one of them had to be the expected or the potential amount of patient that will be on the drug anually. By looking at page 11 and 12, we can see that less there are patient on an orphan drug, more expensive the drug will be. Page 12 clearly indicate that an orphan drug at a cost of around $120 000 per year, the amount of patient per year is between 6000 and 7000. Can we take this as a additionnal clue about how many patient TH and Taimed are expecting to be on the drug ?
Ref: https://info.evaluategroup.com/rs/607-YGS-364/images/EPOD17.pdf